{"id":16811,"date":"2018-08-08T01:57:47","date_gmt":"2018-08-08T01:57:47","guid":{"rendered":"http:\/\/thepatientinvestor.com\/?p=16811"},"modified":"2018-08-09T01:09:03","modified_gmt":"2018-08-09T01:09:03","slug":"appen-limited-apx","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/","title":{"rendered":"Appen Limited (APX)"},"content":{"rendered":"<p>Stock: <strong>Appen Limited<\/strong><br \/>\nSymbol: <strong>APX<\/strong><br \/>\nExchange: ASX<\/p>\n<p>Appen was added to the ASX 200 in June 2018 and displays strong performance in both LT technical and revenue &amp; earnings growth.<\/p>\n<p><img data-recalc-dims=\"1\" decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2018\/apx-lt.png?w=525&#038;ssl=1\" alt=\"Appen Limited (APX)\" \/><\/p>\n<p>Despite this, we have <strong>not added APX to our model portfolio<\/strong>, or issued a buy signal, because of its market position.<\/p>\n<p>We are looking for companies with a competitive advantage that enables them to defend market share against competitors, without compromising profit margins.<\/p>\n<p>APX competes in a crowded, technology-driven market against a vast number of competitors (over 17,500 Content Relevance and Language Resources providers, according to Jacob Simonsen at <em>Lincoln<\/em>) and is vulnerable to technology advances by competitors that could make it difficult for APX to defend its market share.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stock: Appen Limited Symbol: APX Exchange: ASX Appen was added to the ASX 200 in June 2018 and displays strong performance in both LT technical and revenue &amp; earnings growth. Despite this, we have not added APX to our model portfolio, or issued a buy signal, because of its market position. We are looking for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Appen Limited (APX)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[40,3799],"tags":[3864,3865],"class_list":["post-16811","post","type-post","status-publish","format-standard","hentry","category-australia-nz-countries-regions","category-asx-growth","tag-appen-limited","tag-apx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Appen Limited (APX) - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Appen Limited (APX) - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Stock: Appen Limited Symbol: APX Exchange: ASX Appen was added to the ASX 200 in June 2018 and displays strong performance in both LT technical and revenue &amp; earnings growth. Despite this, we have not added APX to our model portfolio, or issued a buy signal, because of its market position. We are looking for &hellip; Continue reading &quot;Appen Limited (APX)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:author\" content=\"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-08-08T01:57:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-08-09T01:09:03+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/static.incrediblecharts.com\/images\/2018\/apx-lt.png\" \/>\n<meta name=\"author\" content=\"Colin Twiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Colin Twiggs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/\"},\"author\":{\"name\":\"Colin Twiggs\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\"},\"headline\":\"Appen Limited (APX)\",\"datePublished\":\"2018-08-08T01:57:47+00:00\",\"dateModified\":\"2018-08-09T01:09:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/\"},\"wordCount\":120,\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2018\\\/apx-lt.png\",\"keywords\":[\"Appen Limited\",\"APX\"],\"articleSection\":[\"Australia &amp; NZ\",\"Australian Growth\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/\",\"name\":\"Appen Limited (APX) - the patient investor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2018\\\/apx-lt.png\",\"datePublished\":\"2018-08-08T01:57:47+00:00\",\"dateModified\":\"2018-08-09T01:09:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2018\\\/apx-lt.png\",\"contentUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2018\\\/apx-lt.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2018\\\/08\\\/08\\\/appen-limited-apx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/thepatientinvestor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Appen Limited (APX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thepatientinvestor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61572934660810\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\",\"name\":\"Colin Twiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"caption\":\"Colin Twiggs\"},\"description\":\"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He founded PVT Capital (AFSL number 546090), which provides income and growth strategies to wholesale clients. Colin also co-founded Incredible Charts and writes the popular Patient Investor newsletter. Using a top-down approach, Colin identifies macro trends in the global economy and then combines fundamental and technical analysis to evaluate opportunities in sectors that stand to benefit. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\\\/2009 and 2020 bear markets well ahead of actual events.\",\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/people\\\/The-Patient-Investor\\\/61572934660810\\\/\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\",\"https:\\\/\\\/au.linkedin.com\\\/in\\\/colintwiggs\"],\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/author\\\/investor\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Appen Limited (APX) - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Appen Limited (APX) - the patient investor","og_description":"Stock: Appen Limited Symbol: APX Exchange: ASX Appen was added to the ASX 200 in June 2018 and displays strong performance in both LT technical and revenue &amp; earnings growth. Despite this, we have not added APX to our model portfolio, or issued a buy signal, because of its market position. We are looking for &hellip; Continue reading \"Appen Limited (APX)\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_author":"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","article_published_time":"2018-08-08T01:57:47+00:00","article_modified_time":"2018-08-09T01:09:03+00:00","og_image":[{"url":"http:\/\/static.incrediblecharts.com\/images\/2018\/apx-lt.png","type":"","width":"","height":""}],"author":"Colin Twiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Colin Twiggs","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/"},"author":{"name":"Colin Twiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454"},"headline":"Appen Limited (APX)","datePublished":"2018-08-08T01:57:47+00:00","dateModified":"2018-08-09T01:09:03+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/"},"wordCount":120,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2018\/apx-lt.png","keywords":["Appen Limited","APX"],"articleSection":["Australia &amp; NZ","Australian Growth"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/","name":"Appen Limited (APX) - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/#primaryimage"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2018\/apx-lt.png","datePublished":"2018-08-08T01:57:47+00:00","dateModified":"2018-08-09T01:09:03+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/#primaryimage","url":"https:\/\/www.incrediblecharts.com\/images\/2018\/apx-lt.png","contentUrl":"https:\/\/www.incrediblecharts.com\/images\/2018\/apx-lt.png"},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Appen Limited (APX)"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454","name":"Colin Twiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","caption":"Colin Twiggs"},"description":"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He founded PVT Capital (AFSL number 546090), which provides income and growth strategies to wholesale clients. Colin also co-founded Incredible Charts and writes the popular Patient Investor newsletter. Using a top-down approach, Colin identifies macro trends in the global economy and then combines fundamental and technical analysis to evaluate opportunities in sectors that stand to benefit. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\/2009 and 2020 bear markets well ahead of actual events.","sameAs":["https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","https:\/\/www.instagram.com\/colin_thepatientinvestor","https:\/\/au.linkedin.com\/in\/colintwiggs"],"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/investor\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-4n9","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":37932,"url":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/","url_meta":{"origin":16811,"position":0},"title":"Appen Ltd (APX)","author":"Colin Twiggs","date":"October 5, 2022","format":false,"excerpt":"Stock: Appen Ltd Exchange: ASX Symbol: APX Date: 05-Oct-22 Latest price: A$3.29 Market Cap: $406 m Fair Value: A$2.99 Forward DY: 3.16% Payback (Years): N\/A Financial Y\/E: 31-Dec-22 Rating: HOLD Sector: Technology Industry: IT Services Investment Theme: Technology Macro Trends: A.I. Summary Appen (APX) is trading at a discount to\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":29844,"url":"https:\/\/thepatientinvestor.com\/index.php\/2021\/12\/10\/australian-growth-performance-at-30-november-2021\/","url_meta":{"origin":16811,"position":1},"title":"Australian Growth: Performance at Nov-2021","author":"Andy","date":"December 10, 2021","format":false,"excerpt":"Australian Growth portfolio performance since inception on 1 July 2018 is set out below. We expect to hold most growth stocks for 5 to 10 years. Individual Stocks The portfolio has a sizable allocation to gold & precious metals (17% at 30-Nov-2021). We expect rising inflation and increasingly negative real\u2026","rel":"","context":"In &quot;Australian Growth Performance&quot;","block_context":{"text":"Australian Growth Performance","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/australian-growth-performance\/"},"img":{"alt_text":"Australian Growth Annualized Performance 1-Jul-2018 to 30-Nov-2021: Portfolio 4.99%, ASX 200 Accumulation Index 8.79%","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/12\/perf-2021-11-aus.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/12\/perf-2021-11-aus.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/12\/perf-2021-11-aus.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":19620,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/01\/15\/asx-leading-sectors\/","url_meta":{"origin":16811,"position":2},"title":"ASX Leading Sectors","author":"Colin Twiggs","date":"January 15, 2020","format":false,"excerpt":"The ASX 200 broke resistance at 6800, signaling a fresh advance. Expect retracement to test the new support level. Respect would strengthen the bull signal, confirming a fresh advance. At the same time, fundamentals are distinctly bearish, with falling retail sales and dwindling GDP growth. So, what sectors are driving\u2026","rel":"","context":"In &quot;Australia &amp; NZ&quot;","block_context":{"text":"Australia &amp; NZ","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/countries-regions\/australia-nz-countries-regions\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":41485,"url":"https:\/\/thepatientinvestor.com\/index.php\/2023\/04\/03\/australian-growth-performance-mar-2023\/","url_meta":{"origin":16811,"position":3},"title":"Australian Growth: Performance Mar-2023","author":"Andy","date":"April 3, 2023","format":false,"excerpt":"Australian Growth portfolio performance since inception on July 1, 2018 is set out below. We expect to hold most growth stocks for 5 to 10 years. Individual Stocks Past Performance Hypothetical $1 million invested in the Australian Growth portfolio on July 1, 2018: Performance Notes: Performance is calculated in Australian\u2026","rel":"","context":"In &quot;Australian Growth Performance&quot;","block_context":{"text":"Australian Growth Performance","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/australian-growth-performance\/"},"img":{"alt_text":"Australian Growth Past Allocations","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":18264,"url":"https:\/\/thepatientinvestor.com\/index.php\/2019\/05\/24\/xero-deep-in-overvalued-territory-xro\/","url_meta":{"origin":16811,"position":4},"title":"Xero deep in overvalued territory (XRO)","author":"Colin Twiggs","date":"May 24, 2019","format":false,"excerpt":"From Morningstar today: \"Cloud-based accounting software firm Xero has booked a strong result but the WAAAX club member remains deep in overvalued territory, says Morningstar. Xero this week reported a solid first half 2019 result, which included a 36 per cent boost in revenue and a 31 per cent jump\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":36719,"url":"https:\/\/thepatientinvestor.com\/index.php\/2022\/08\/25\/asx-limited-asx\/","url_meta":{"origin":16811,"position":5},"title":"ASX Limited (ASX)","author":"Colin Twiggs","date":"August 25, 2022","format":false,"excerpt":"We increased our fair value estimate for ASX Limited (ASX) by 3%, to A$44.90 per share, based on the following long-term projections: real organic annual revenue growth of 2% (formerly 4%); EBITDA margin of 74.0% (formerly 76.5%); capital expenditure of 10% of revenue; zero working capital increases; and an effective\u2026","rel":"","context":"In &quot;Australian Growth&quot;","block_context":{"text":"Australian Growth","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/asx-growth\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/16811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=16811"}],"version-history":[{"count":4,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/16811\/revisions"}],"predecessor-version":[{"id":16815,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/16811\/revisions\/16815"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=16811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=16811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=16811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}